Abstract
We have identified parameters which define a causal role of HPV16 in head and neck cancer. Twenty-eight tumours which were typed positive for HPV16 DNA, were comprehensively analysed for expression of the viral oncogenes E6 and E7, the status of the p53 gene, and the protein status of pRb and p16INK4a. In a subset of cases, we have searched for integrated viral DNA, and have determined the genomic status of the E6 gene. Expression of E6/E7 was found in 12 tumours most of which were derived from the oropharynx, whereas p53 mutations were present in 13 tumours from various sites. The tumours either carried p53 mutations but did not express E6/E7, or they did express E6/E7 but were p53-wild-type. Coexistence of E6/E7 expression with a mutated p53 was found in only one case. Strikingly, in most p53-mutated tumours without E6/E7 expression, we found the E6 gene to be disrupted. E6/E7 expression was associated with reduced pRb and overexpressed p16INK4a. Viral-cellular fusion transcripts were found in two cases. Our data demonstrate that HPV16 DNA-positivity in head and neck cancers is not indicative of a causal role. A causal role of HPV16 in head and neck cancer is defined by: E6/E7 expression, viral integration with an intact E6 gene, and perturbation of pRb cell cycle control. Mostly, the p53 gene is wild-type.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Andl T, Kahn T, Pfuhl A, Nicola T, Erber R, Conradt C, Klein W, Helbig M, Dietz A, Weidauer H, Bosch FX . 1998 Cancer Res. 58: 5–13
Barten M, Ostwald C, Milde-Langosch K, Muller P, Wukasch Y, Loning T . 1995 Virchows Arch. 427: 153–157
Berumen J, Casas L, Segura E, Amezcua JL, Garcia-Carranca A . 1994 Int. J. Cancer 56: 640–645
Chiba I, Shindoh M, Yasuda M, Yamazaki Y, Amemiya A, Sato Y, Fujinaga K, Notani K, Fukuda H . 1996 Oncogene 12: 1663–1668
Crook T, Wrede D, Tidy JA, Mason WP, Evans DJ, Vousden KH . 1992 Lancet 339: 1070–1073
Cullen AP, Reid R, Campion M, Lörincz AT . 1991 J. Virol. 65: 606–612
de Villiers EM, Weidauer H, Otto H, zur Hausen H . 1985 Int. J. Cancer 36: 575–578
Dyson N, Howley PM, Munger K, Harlow E . 1989 Science 243: 934–937
el Awady MK, Kaplan JB, O'Brien SJ, Burk RD . 1987 Virology 159: 389–398
Erber R, Conradt C, Homann N, Enders C, Finckh M, Dietz A, Weidauer H, Bosch FX . 1998 Oncogene 16: 1671–1679
Fujita M, Inoue M, Tanizawa O, Iwamoto S, Enomoto T . 1992 Cancer Res. 52: 5323–5328
Gardiol D, Banks L . 1998 J. Gen. Virol. 79: 1963–1970
Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D . 2000 J. Natl. Cancer Inst. 92: 709–720
Grüttgen A, Reichenzeller M, Junger M, Schlien S, Affolter A, Bosch FX . 2001 J. Pathol. 194: 311–317
Harrington JJ, Sherf B, Rundlett S, Jackson PD, Perry R, Cain S, Leventhal C, Thornton M, Ramachandran R, Whittington J, Lerner L, Costanzo D, McElligott K, Boozer S, Mays R, Smith E, Veloso N, Klika A, Hess J, Cothren K, Lo K, Offenbacher J, Danzig J, Ducar M . 2001 Nat. Biotechnol. 19: 440–445
He D, Zhang DK, Lam KY, Ma L, Ngan HYS, Liu SS, Tsao SW . 1997 Int. J. Cancer 72: 959–964
Hoppe-Seyler F, Butz K . 1994 Mol. Carcinog. 10: 134–141
Jacobs MV, de Roda Husman AM, van den Brule AJC, Snijders PJF, Meijer CJLM, Walboomers JMM . 1995 J. Clin. Microbiol. 33: 901–905
Kahn T, Turazza E, Ojeda R, Bercovich A, Stremlau A, Lichter P, Poustka A, Grinstein S, zur Hausen H . 1994 Cancer Res. 54: 1305–1312
Klaes R, Woerner SM, Ridder R, Wentzensen N, Duerst M, Schneider A, Lotz B, Melsheimer P, von Knebel Doeberitz M . 1999 Cancer Res. 59: 6132–6136
Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, Dallenbach-Hellweg G, Schmidt D, von Knebel Doeberitz M . 2001 Int. J. Cancer 92: 276–284
Luft F, Klaes R, Nees M, Duerst M, Heilmann V, Melsheimer P, von Knebel-Doeberitz M . 2001 Int. J. Cancer 92: 9–17
Maitland NJ, Cox MF, Lynas C, Prime SS, Meanwell CA, Scully C . 1987 Br. J. Cancer 56: 245–250
Matsukura T, Koi S, Sugase M . 1989 Virology 172: 63–72
Milde-Langosch K, Albrecht K, Joram S, Schlechte H, Giessing M, Löning T . 1995 Int. J. Cancer 63: 639–645
Nakajima-Iijima S, Hamada H, Reddy P, Kakunaga T . 1985 Proc. Natl. Acad. Sci. USA 82: 6133–6137
Rassekh CH, Rady PL, Arany I, Tyring SK, Knudsen S, Calhoun KH, Seikaly H, Bailey BJ . 1998 Laryngoscope 108: 362–367
Resnick RM, Cornelissen MTE, Wright DK, Eichinger GH, Fox HS, ter Schegget J, Manos MM . 1990 J. Natl. Cancer Inst. 82: 1477–1484
Scholes AGM, Liloglou T, Snijders PJF, Hart CA, Jones AS, Woolgar JA, Vaughan ED, Walboomers JMM, Field JK . 1997 Int. J. Cancer 71: 796–799
Scheffner M, Münger K, Byrne JC, Howley PM . 1991 Proc. Natl. Acad. Sci. USA 88: 5523–5527
Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A, zur Hausen H . 1985 Nature 314: 111–114
Seedorf K, Kraemmer G, Duerst M, Suhai S, Roewekamp WG . 1985 Virology 145: 181–185
Snijders PJF, Crommi FV, van den Brule AJC, Schrijnemakers HFJ, Snow GB, Meijer CJLM, Walboomers JMM . 1992 Int. J. Cancer 51: 845–850
Steenbergen RDM, Hermsen MAJA, Walboomers JMM, Joenje H, Arwert F, Meijer CJLM, Snijders PJF . 1995 Cancer Res. 55: 5465–5471
van den Brule AJ, Claas EC, du Maine M, Melchers WJ, Helmerhorst T, Quint WG, Lindeman J, Meijer CJ, Walboomers JM . 1989 J. Med. Virol. 29: 20–27
van Houten VMM, Snijders PJF, van den Brekel MWM, Kummer JA, Meuer CJLM, van Leeuwen B, Denkers F, Smeele LE, Snow GB, Brakenhoff RH . 2001 Int. J. Cancer 93: 232–235
von Knebel-Doeberitz M, Oltersdorf T, Schwarz E, Gissmann L . 1988 Cancer Res. 48: 3780–3786
Wilczynksi SP, Lin BTY, Xie Y, Paz IB . 1998 AJP 152: 145–156
Yeudall WA, Campo MS . 1991 J. Gen. Virol. 72: 173–176
zur Hausen H . 1996 Biochim. Biophys. Acta. 1288: F55–F78
Acknowledgements
We are greatly indebted to Drs A Dietz, C Reißer, AJ Tasman and F Wallner for collecting and processing the tissue specimens, P Tomakidi and L Gissmann for fruitful discussions, and H Weidauer for support. We also thank S Huntgeburth, A Schuhmann, A Kohl, C Lokrey and F Devens for their excellent technical assistance. P Benjamin is acknowledged for photographical work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wiest, T., Schwarz, E., Enders, C. et al. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 21, 1510–1517 (2002). https://doi.org/10.1038/sj.onc.1205214
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205214
Keywords
This article is cited by
-
p16INK4a and pRb expression in laryngeal squamous cell carcinoma with and without infection by EBV or different genotypes of HPV: a retrospective study
Infectious Agents and Cancer (2023)
-
High-risk HPV infection-associated hypermethylated genes in oropharyngeal squamous cell carcinomas
BMC Cancer (2022)
-
Folate functionalized gold-coated magnetic nanoparticles effect in combined electroporation and radiation treatment of HPV-positive oropharyngeal cancer
Medical Oncology (2022)
-
Discrepancy in p16 expression in patients with HPV-associated head and neck squamous cell carcinoma in Thailand: clinical characteristics and survival outcomes
BMC Cancer (2021)
-
CDK4/6 inhibitors in P16/HPV16-negative squamous cell carcinoma of the head and neck
European Archives of Oto-Rhino-Laryngology (2020)